The medication, Orotecan®, is a novel oral formulation of irinotecan, an intravenous drug that has demonstrated efficacy in ...

Lupus nephritis is a major cause of mortality in patients with systemic lupus erythematosus (SLE), and the drugs currently used to treat this disease, such as cyclophosphamide, prednisolone ...

A four-drug chemotherapy regimen of irinotecan liposome (Onivyde) in combination with oxaliplatin, leucovorin, and ...

In 2002, the Japan Clinical Oncology Group (JCOG) reported data from a phase III trial (n = 154) demonstrating that the substitution of irinotecan for etoposide, when combined with cisplatin, was ...

In this particular study, treatment-related mortality occurred in 5.3% and 1.6% of patients receiving irinotecan weekly and every three weeks, respectively. Determining a patient's genotype status ...

During the past few years, six clinical trials have been published on the treatment of advanced or metastatic gastric and gastroesophageal cancer using the combination capecitabine and irinotecan.

irinotecan, or pemetrexed) in 502 patients with recurrent or metastatic cervical cancer who received no more than 2 prior systemic regimens in the recurrent or metastatic setting. The primary outcome ...

Patients with SCLC and progression on or after first-line platinum-based chemotherapy were randomly assigned (1:1) to intravenous (IV) liposomal irinotecan (70 mg/m 2 every 2 weeks in a 6-week cycle) ...

The Starpharma Holdings Limited (ASX: SPL) share price has pushed higher on Thursday following the release of an update on its DEP irinotecan formulation. At the time of writing the dendrimer ...

Besides the mCRC indication, CRDF is also currently evaluating the safety and preliminary efficacy of onvansertib in ...

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for ...

NUC-3373 is currently being evaluated in three ongoing clinical studies: a Phase 1b/2 study (NuTide:302) in combination with leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients with ...